TIMI risk score for secondary prevention of recurrent cardiovascular events in a real-world cohort of post-non-ST-elevation myocardial infarction patients
| Autor: | Ji Yan Chen, Ming Xiang Wu, Xi Su, Cheung Chi Simon Lam, Ki Chan, Ka Lam Wong, Ning Tan, Pak-Hei Chan, Hua Yan, Chor Cheung Tam, Chu-Pak Lau, Ying Qing Feng, Yang Yang Cheng, Yiu Tung Wong, Duo Huang, Jo-Jo Hai, Hung-Fat Tse, See Yue Yung, Chung-Wah Siu, Dan Song |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Kaplan-Meier Estimate Disease 030204 cardiovascular system & hematology Risk Assessment Brain Ischemia 03 medical and health sciences 0302 clinical medicine Predictive Value of Tests Recurrence St elevation myocardial infarction Cause of Death Internal medicine Secondary Prevention medicine Humans Registries Survivors 030212 general & internal medicine Myocardial infarction Acute Coronary Syndrome Non-ST Elevated Myocardial Infarction Aged Retrospective Studies Aged 80 and over Secondary prevention Academic Medical Centers Framingham Risk Score business.industry General Medicine Middle Aged medicine.disease Survival Analysis Stroke Cardiovascular Diseases Cohort Hong Kong Female Observational study business TIMI |
| Zdroj: | Postgraduate Medical Journal. 95:372-377 |
| ISSN: | 1469-0756 0032-5473 |
| Popis: | Background Patients who survive non-ST-elevation myocardial infarction (NSTEMI) are at heightened risk of recurrent cardiovascular events. Data on long-term secondary atherothrombotic risk stratification are limited. Objectives To stratify post-NSTEMI patients for risk of recurrent cardiovascular events to maximise benefit from aggressive secondary prevention strategies using the TIMI Risk Score for Secondary Prevention (TRS 2°P) score in a real-world cohort of NSTEMI patients. Methods and results This was a single-centre observational study of 891 post-NSTEMI patients (73.7 ± 12.7 years; male: 54.2%). The TRS 2°P is a nine-point risk stratification tool to predict cardiovascular events in patients with established cardiovascular disease. The primary outcome was a composite endpoint of cardiovascular death, non-fatal MI and non-fatal ischaemic stroke. After a median follow-up of 31 months (IQR: 11.4 – 60.2), 281 patients (31.5%) had developed a primary outcome (13.3%/year) including 196 cardiovascular deaths, 94 non-fatal MIs and 22 non-fatal strokes. The TRS 2°P score was strongly associated with the primary outcome. The annual incidence of primary composite endpoint for patients with TRS 2°P score =0 was 1.6%, and increased progressively to 47.4% for those with a TRS 2°P score ≥6 (HR: 20.18, 95% CI: 4.85 to 84.05, p Conclusion The TRS 2°P score stratified post-NSTEMI patients for risk of future cardiovascular events and potentially help guide the selection of more aggressive secondary prevention therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|